These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 401123)

  • 1. Monitoring of hormonal therapy in patients with metastatic breast carcinoma by plasma marker protein profiles.
    Haagensen DE; Dilley WG; Cox CE; Giannola JE; Wells SA
    Surg Forum; 1978; 29():162-4. PubMed ID: 401123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen stimulation of gross cystic disease fluid protein and carcinoembryonic antigen in patients with metastatic breast carcinoma.
    Dilley WG; Leight GS; Silva JS; Ammirata S; Haagensen DE; Wells SA
    J Natl Cancer Inst; 1983 Jan; 70(1):69-74. PubMed ID: 6571924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of CEA and GCDFP-15 plasma level during hormonally induced cancer stimulation.
    Manni A; Santen RJ; Boucher AE; Lipton A; Harvey H; Drago J; Rohner T; Haagensen D; Glode M; Santner SJ
    Anticancer Res; 1984; 4(3):141-4. PubMed ID: 6380398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoperoxidase staining for tumor markers in patients with carcinoma of the breast.
    Cox CE; Haagensen DE; Dilley WG; Wells SA
    Surg Forum; 1978; 29():160-2. PubMed ID: 401405
    [No Abstract]   [Full Text] [Related]  

  • 5. The value of serial plasma levels of carcinoembryonic antigen and gross cyst disease fluid protein in patients with breast carcinoma and osseous metastases.
    Haagensen DE; Barry WF; McCook TA; Giannola J; Ammirata S; Wells SA
    Ann Surg; 1980 May; 191(5):599-603. PubMed ID: 7369822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of response to therapy in patients with metastatic breast carcinoma by serial analysis of plasma gross cystic disease fluid protein and carcinoembryonic antigen.
    Silva JS; Leight GS; Haagensen DE; Tallos PB; Cox EB; Dilley WG; Wells SA
    Cancer; 1982 Mar; 49(6):1236-42. PubMed ID: 6174201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers for breast carcinoma.
    Haagensen DE
    Clin Lab Med; 1982 Sep; 2(3):543-65. PubMed ID: 6754225
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
    Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
    Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic breast carcinoma presenting as endometrial cancer. A case report.
    Lallas TA; Taskin M; Calanog A; Shevchuk MM
    J Reprod Med; 1997 Feb; 42(2):121-3. PubMed ID: 9058349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is there value in determining tumor markers in senology?].
    Van Cauwenberge JR; Collette J; Franchimont P
    Rev Med Liege; 1995 Jan; 50(1):41-5. PubMed ID: 7871286
    [No Abstract]   [Full Text] [Related]  

  • 12. Signet ring variant of lobular carcinoma of the breast: a clinicopathologic and immunohistochemical study.
    Raju U; Ma CK; Shaw A
    Mod Pathol; 1993 Sep; 6(5):516-20. PubMed ID: 8248106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative evaluation of carcinoembryonic antigen and gross cystic disease fluid protein as plasma markers for human breast carcinoma.
    Haagensen DE; Kister SJ; Panick J; Giannola J; Hansen HJ; Wells SA
    Cancer; 1978 Sep; 42(3 Suppl):1646-52. PubMed ID: 709529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen and progesterone receptors and anti-gross cystic disease fluid protein 15 (BRST-2) fail to distinguish metastatic breast carcinoma from eccrine neoplasms.
    Wallace ML; Longacre TA; Smoller BR
    Mod Pathol; 1995 Dec; 8(9):897-901. PubMed ID: 8751328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma.
    Dilley WG; Haagensen DE; Leight GS; Ammirata S; Davis SR; Silva JS; Zamcheck N; Lokich JJ; Wells SA
    Breast Cancer Res Treat; 1986; 8(3):205-15. PubMed ID: 3593986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gross cystic disease fluid protein (GCDFP-15) in the breast: past and present.
    Sapino A; Cassoni P; Bussolati G
    J Biol Regul Homeost Agents; 2000; 14(4):259-62. PubMed ID: 11215813
    [No Abstract]   [Full Text] [Related]  

  • 17. [Breast carcinoma metastatic to meningioma: review of the literature and description of 2 new cases].
    Fornelli A; Bacci A; Collina G; Eusebi V
    Pathologica; 1995 Oct; 87(5):506-12. PubMed ID: 8868176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apocrine carcinoma of the breast. A cytological, immunohistochemical and ultrastructural study of 6 cases.
    Alexiev B; Boschnakova Z; Prokopanov C
    Zentralbl Pathol; 1994 Jul; 140(2):129-34. PubMed ID: 7524651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical correlates of morphologic differentiation in human breast cancer.
    Silva JS; Cox CE; Wells SA; Paull D; Dilley WG; McCarty KS; Fetter BF; Glaubitz LC; McCarty KS
    Surgery; 1982 Sep; 92(3):443-9. PubMed ID: 7202259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
    Lee BH; Hecht JL; Pinkus JL; Pinkus GS
    Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.